These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34039750)

  • 1. Nodal and paranodal antibody-associated neuropathies.
    Fehmi J; Vale T; Keddie S; Rinaldi S
    Pract Neurol; 2021 May; ():. PubMed ID: 34039750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodo-paranodopathies: Concepts, Clinical Implications, and Management.
    Khadilkar SV; Kamat S; Patel R
    Ann Indian Acad Neurol; 2022; 25(6):1001-1008. PubMed ID: 36911467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground.
    Uncini A; Vallat JM
    J Neurol Neurosurg Psychiatry; 2018 Jun; 89(6):627-635. PubMed ID: 29248893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune nodopathies, an emerging diagnostic category.
    Martín-Aguilar L; Lleixà C; Pascual-Goñi E
    Curr Opin Neurol; 2022 Oct; 35(5):579-585. PubMed ID: 35989582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mechanisms in inflammatory and paraproteinaemic peripheral neuropathies.
    Rinaldi S; Bennett DL
    Curr Opin Neurol; 2014 Oct; 27(5):541-51. PubMed ID: 25159930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies.
    Doppler K; Appeltshauser L; Wilhelmi K; Villmann C; Dib-Hajj SD; Waxman SG; Mäurer M; Weishaupt A; Sommer C
    J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):720-8. PubMed ID: 25694474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrastructural Lesions of Nodo-Paranodopathies in Peripheral Neuropathies.
    Vallat JM; Magy L; Corcia P; Boulesteix JM; Uncini A; Mathis S
    J Neuropathol Exp Neurol; 2020 Mar; 79(3):247-255. PubMed ID: 31923310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment.
    Uncini A
    J Peripher Nerv Syst; 2023 Jul; 28 Suppl 3():S23-S35. PubMed ID: 37272673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodal-paranodal antibodies in HIV-immune mediated radiculo-neuropathies: Clinical phenotypes and relevance.
    Moodley K; Patel VB; Moodley AA; Bill PLA; Kajee A; Mgbachi V; Fehmi J; Rinaldi S
    J Peripher Nerv Syst; 2023 Dec; 28(4):578-585. PubMed ID: 37676746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies.
    Davies AJ; Fehmi J; Senel M; Tumani H; Dorst J; Rinaldi S
    J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32605107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune mechanisms, the role of complement, and related therapies in autoimmune neuropathies.
    Latov N
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1269-1281. PubMed ID: 34751638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
    Briani C; Visentin A
    Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
    Manso C; Querol L; Mekaouche M; Illa I; Devaux JJ
    Brain; 2016 Jun; 139(Pt 6):1700-12. PubMed ID: 27017186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growing Spectrum of Autoimmune Nodopathies.
    Gupta P; Mirman I; Shahar S; Dubey D
    Curr Neurol Neurosci Rep; 2023 May; 23(5):201-212. PubMed ID: 37014546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.
    Bresciani L; Salvalaggio A; Vegezzi E; Visentin A; Fortuna A; Anglani M; Cacciavillani M; Masciocchi S; Scaranzin S; Carecchio M; Martinuzzi A; Gastaldi M; Briani C
    J Peripher Nerv Syst; 2023 Sep; 28(3):522-527. PubMed ID: 37246762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing.
    Roggenbuck D; Delmont E; Reinhold D; Schierack P; Conrad K; Boucraut J
    Mediterr J Rheumatol; 2020 Mar; 31(1):10-18. PubMed ID: 32411930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.
    Appeltshauser L; Messinger J; Starz K; Heinrich D; Brunder AM; Stengel H; Fiebig B; Ayzenberg I; Birklein F; Dresel C; Dorst J; Dvorak F; Grimm A; Joerk A; Leypoldt F; Mäurer M; Merl P; Michels S; Pitarokoili K; Rosenfeldt M; Sperfeld AD; Weihrauch M; Welte GS; Sommer C; Doppler K
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35314491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.
    Doppler K; Appeltshauser L; Villmann C; Martin C; Peles E; Krämer HH; Haarmann A; Buttmann M; Sommer C
    Brain; 2016 Oct; 139(Pt 10):2617-2630. PubMed ID: 27474220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies.
    Uncini A
    Exp Neurol; 2012 Jun; 235(2):513-6. PubMed ID: 22507308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are Miller Fisher syndrome and CANDA due to a paranodopathy?
    Vallat JM; Deschamps N; Taithe F; Richard L; Duchesne M; Magy L; Mathis S
    J Neurol Sci; 2022 Jul; 438():120279. PubMed ID: 35576641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.